Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T16:03:45.378Z.
Calculation as of: 2026-10-06T16:03:45.378Z.
Quote observation: 2026-10-06T16:00:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: caaf80bca5ccea9457018b34cf7693b2821ca050e30c360cba938cf84e67b366
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
LB Pharmaceuticals Inc Common Stock
Market Cap
$1.00B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$993.24M
Operating Cash Flow Yield
1.38%
TTM Avg
0.99%
3Y Avg
0.99%
5Y Avg
0.99%
Market Cap
$990.91M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.01B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$988.29M
Operating Cash Flow Yield
18.99%
TTM Avg
14.96%
3Y Avg
15.37%
5Y Avg
11.65%
Market Cap
$987.23M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02B
Operating Cash Flow Yield
6.34%
TTM Avg
6.00%
3Y Avg
6.00%
5Y Avg
6.00%
Market Cap
$1.03B
Operating Cash Flow Yield
8.25%
TTM Avg
7.29%
3Y Avg
7.32%
5Y Avg
6.78%
Market Cap
$956.88M
Operating Cash Flow Yield
N/A
TTM Avg
16.88%
3Y Avg
16.91%
5Y Avg
16.91%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LB Pharmaceuticals Inc Common Stock (LBRX) | $1.00B | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $993.24M | 1.38% | 0.99% | 0.99% | 0.99% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $990.91M | N/A | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $1.01B | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $988.29M | 18.99% | 14.96% | 15.37% | 11.65% |
| Aktis Oncology, Inc. (AKTS)vs › | $987.23M | N/A | N/A | N/A | N/A |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 6.34% | 6.00% | 6.00% | 6.00% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | 8.25% | 7.29% | 7.32% | 6.78% |
| Kura Oncology, Inc. (KURA)vs › | $956.88M | N/A | 16.88% | 16.91% | 16.91% |
| Immatics N.V. (IMTX)vs › | $1.04B | N/A | 1.54% | 13.01% | 70.14% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
